第 4 项适应症!翰森制药“阿美替尼”获批用于 NSCLC 辅助治疗

Insight数据库
09 May

5 月 9 日,NMPA 官网显示,翰森制药“甲磺酸阿美替尼片”(阿美乐®)获批一项新适应症(受理号:CXHS2400060),用于具有表皮生长因素受体(EGFR)外显子 19 缺失或外显子 21(L858R)置换突变阳性的非小细胞肺癌(NSCLC)成人患者肿瘤切除术后的辅助治疗。截图来源:NMPA 官网值得一提的是,这是阿美替尼获批上市的第 4 项适应症。阿美替尼由翰森制药研发,该药创新性地引入...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10